Key result
Trial evaluates ICMs versus standard monitoring for AF detection in HF with LVEF >35%.
Why the study?
Heart failure patients face high risks of complications from undiagnosed atrial fibrillation, but limited modalities currently exist for early detection in this population.
Does an Abbott implantable cardiac monitor improve the time to first detection of atrial fibrillation compared to standard monitoring in symptomatic heart failure patients with LVEF > 35%?
RCT (n=477)
Nonblinded
2:1 ratio, stratified by degree of LV dysfunction
Yes
Does an Abbott implantable cardiac monitor improve the time to first detection of atrial fibrillation compared to standard monitoring in symptomatic heart failure patients with LVEF > 35%?
The Confirm-AF trial is designed to determine whether implantable cardiac monitors can increase early detection of atrial fibrillation in heart failure patients with preserved or mildly reduced ejection fraction.
Answers are grounded in this paper and cite their sources.
RCT data on ICM for AF detection in HF with LVEF >35% forthcoming; leaves open impact on outcomes.
BACKGROUND: Patients with heart failure (HF) represent a large population of patients who are at high risk for complications related to undiagnosed atrial fibrillation (AF). However, currently there are limited modalities available for early AF detection in this high-risk population. An implantable cardiac monitor (ICM) is inserted subcutaneously and can provide long-term arrhythmia information via remote monitoring. METHODS AND RESULTS: Confirm-AF is a prospective randomized, nonblinded, two arm, multicenter clinical trial to be performed in the United States, enrolling 477 patients with a history of HF hospitalization and left ventricular ejection fraction >35% from 30 medical sites. Patients will be randomized in a 2:1 fashion to undergo ICM implant with remote monitoring and symptom-triggered mobile app transmissions versus (vs.) Non-ICM management and follow-up. The primary objective of this trial is to compare the time to first detection of AF lasting > 5 min using an Abbott ICM compared to non-ICM monitoring in symptomatic HF patients. This article describes the design and analytic plan for the Confirm-AF trial. CONCLUSIONS: The Confirm-AF trial seeks to accurately define the burden of AF in high-risk HF patients with LVEF > 35% using an Abbott ICM. A finding showing significantly higher incidence of AF along with improved clinical outcomes with ICM monitoring is expected to have substantial clinical implications and may change the method of monitoring high-risk HF patients.
No takes yet. Share an insight, caveat, or question.
Aktaş et al. (2022) conducted an RCT in Heart failure with LVEF > 35% and recent hospitalization (n=477). Abbott implantable cardiac monitor (ICM) vs. Non-ICM management (standard care) was evaluated on Time to first detection of atrial fibrillation (AF) lasting > 5 min. Abbott implantable cardiac monitors will be evaluated for their efficacy in detecting atrial fibrillation compared to standard monitoring in 477 patients with heart failure and LVEF > 35%.
Synapse has enriched 10 related papers. Consider them for comparative context: